Oncology

News

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

FDA has sent a complete response letter to J&J, denying approval of its subcutaneous version of lung cancer therapy Rybrevant.

Oncology

In a new report, ‘Helping others: unlocking the potential of

News

A study has confirmed that colorectal cancer is rising in younger adults around the world, with England among countries seeing the fastest rise.

News

A single year of adjuvant treatment with AstraZeneca and MSD's PARP inhibitor Lynparza is still providing a survival benefit six years later.

News

Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.